DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists' existing workflow. The lead product Histotype PxColorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.

The company was established to meet the need for novel methods in precision medicine to personalize treatment for cancer patients. It builds on prominent research from Oslo University Hospital, Oxford University, and University College of London. Selected as a Lighthouse project by the Norwegian Research Council, DoMore Diagnostics develops new diagnostic methods for cancer based on artificial intelligence.

The project was led by the late Prof. Hvard Danielsen, aiming to utilize new AI technology in digital pathology to reduce over- and undertreatment in cancer. The company seeks to bring AI-powered digital biomarkers closer to clinicians and patients, enabling personalized cancer treatment to improve patient outcomes and lower healthcare costs globally.